A personalized mRNA vaccine tested at UC San Francisco has become the first to successfully prevent the return and spread of cancer in late-stage clinical trials. The results could signal a new era of vaccines to treat a range of cancers, says UCSF Professor of Medicine Adil Daud, MD, who led the university’s trial site.